PharmaTher Holdings Ltd. (PHRRF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $3.55M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPharmaTher Holdings Ltd. (PHRRF) trades at $0.039. PharmaTher Holdings Ltd. is a clinical-stage psychedelics biotech company focused on developing novel uses and delivery methods for psychedelics to treat mental illness, neurological, and pain disorders. Market cap: $3.55M, Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for PHRRF: PHRRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
PharmaTher Holdings Ltd. (PHRRF) Healthcare & Pipeline Overview
PharmaTher Holdings Ltd. is a clinical-stage biotech company specializing in psychedelic-based therapeutics targeting mental health, neurological, and pain disorders. Their focus on ketamine-based treatments and innovative delivery methods like microneedle patches positions them in the emerging psychedelic medicine market, competing with both established pharmaceutical firms and other biotech startups.
What Is the Investment Thesis for PHRRF?
PharmaTher Holdings Ltd. presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine market. The company's focus on ketamine-based therapies and innovative delivery methods addresses a significant unmet need in mental health, neurological, and pain disorders. Key value drivers include the successful completion of ongoing clinical trials for its ketamine products, particularly the Phase II and III trials for Ketamine intravenous injection. Positive clinical data could lead to significant market valuation increases. The company's collaboration agreements also de-risk development. However, the company faces significant regulatory hurdles and competition. As of 2026-03-16, the company's market capitalization is $3.55M and P/E ratio is -4.66.
Based on FMP financials and quantitative analysis
PHRRF Key Highlights
Ketamine Intravenous Injection is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications.
- Ketamine Patch is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders.
- Ketamine Pump is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure.
- The company is developing PHARMAPATCH, a microneedle patch to deliver psychedelics.
- PharmaTher has collaboration agreements with LTS Lohmann Therapie-Systeme AG, Alcami Corporation, BioRAE, Inc., Revive Therapeutics Ltd., and Gesval S.A.
Who Are PHRRF's Competitors?
PHRRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BETRF BetterLife Pharma Inc. | $0.19 | -4.88% | $30.9M | — |
| CUBT Curative Biotechnology, Inc. | $0.93 | 0.00% | $6.34M | — |
| GLWLF Glow Lifetech Corp. | $0.03 | 0.00% | $6.69M | — |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PHRRF's Key Strengths?
Innovative drug delivery technologies (e.g., microneedle patch).
- Focus on ketamine, a well-studied psychedelic with established uses.
- Strategic collaborations with established companies.
- Pipeline of products in various stages of clinical trials.
What Are PHRRF's Weaknesses?
Limited financial resources as a clinical-stage company.
- Dependence on successful clinical trial outcomes.
- High regulatory hurdles for psychedelic-based therapies.
- Small market capitalization.
What Could Drive PHRRF Stock Higher?
PHRRF catalyst: Announcement of Phase II clinical trial results for Ketamine Pump in metal health, pain disorders, and surgery/procedure by Q4 2026.
- Initiation of Phase III clinical trials for Ketamine intravenous injection for anesthesia and sedation by Q2 2027.
- Continued development of PHARMAPATCH microneedle patch for delivery of psychedelics, with potential for preclinical data release by Q1 2027.
- Expansion of strategic partnerships to accelerate product development and commercialization throughout 2026.
- Progress in securing regulatory approvals for ketamine-based therapies in various jurisdictions throughout 2026 and 2027.
What Are the Key Risks for PHRRF?
Financial-distress signal — its Altman Z-Score of -11.98 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for its psychedelic-based therapies.
- Adverse side effects or safety concerns in clinical trials.
- Competition from established pharmaceutical companies and other biotech startups.
- Limited financial resources to fund research and development.
- Dependence on key personnel and strategic partnerships.
What Are the Growth Opportunities for PHRRF?
- Advancement of Ketamine Intravenous Injection: Successful completion of Phase II and III clinical trials for Ketamine intravenous injection for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications could lead to FDA approval and commercialization. The market for Parkinson's disease treatment is projected to reach $5.9 billion by 2028. Positive trial outcomes by late 2027 could drive significant revenue growth.
- Development of Ketamine Patch: The Ketamine Patch, currently in Phase I and II clinical trials, targets depression, mental health, complex regional pain syndrome, and pain disorders. The global market for pain management is expected to reach $52 billion by 2027. Successful development and approval of the Ketamine Patch by 2028 could capture a significant share of this market.
- Commercialization of Ketamine Pump: The Ketamine Pump, in Phase II clinical trial, aims to treat metal health, pain disorders, and surgery/procedure related pain. The market for drug delivery systems is projected to reach $24 billion by 2027. A successful trial outcome and subsequent commercialization by 2028 would provide a novel delivery method for ketamine and generate revenue.
- Expansion of PHARMAPATCH: The development of PHARMAPATCH, a microneedle patch to deliver psychedelics, represents a novel delivery method. The microneedle drug delivery market is expected to reach $1.4 billion by 2027. Successful development and commercialization of PHARMAPATCH by 2029 could establish PharmaTher as a leader in psychedelic delivery technology.
- Strategic Partnerships: PharmaTher's existing collaboration agreements with LTS Lohmann Therapie-Systeme AG, Alcami Corporation, BioRAE, Inc., Revive Therapeutics Ltd., and Gesval S.A. can be leveraged to accelerate product development and expand market reach. Forming new partnerships with pharmaceutical companies or research institutions could provide access to additional resources and expertise, driving growth and innovation in the psychedelic medicine space.
What Are PHRRF's Competitive Advantages?
- Proprietary formulations and delivery methods for psychedelic drugs.
- Patent protection for its innovative technologies.
- Clinical data supporting the safety and efficacy of its products.
- Strategic partnerships with leading companies in the pharmaceutical and biotechnology industries.
What Does PHRRF Do?
PharmaTher Holdings Ltd., incorporated in 2019 and headquartered in Toronto, Canada, is a clinical-stage biotechnology company focused on the research, development, and commercialization of psychedelic pharmaceuticals. The company aims to create novel uses, formulations, and delivery methods of psychedelics, primarily ketamine, to address unmet needs in mental illness, neurological disorders, and pain management. PharmaTher's pipeline includes Ketamine intravenous injection in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis. They are also developing a Ketamine Patch in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders, and a Ketamine Pump in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. Additionally, the company is developing PHARMAPATCH, a microneedle patch for delivering psychedelics. PharmaTher has established collaboration agreements with companies like LTS Lohmann Therapie-Systeme AG, Alcami Corporation, BioRAE, Inc., Revive Therapeutics Ltd., and Gesval S.A. to advance its product development efforts.
What Products and Services Does PHRRF Offer?
- Researches and develops novel uses of psychedelics.
- Creates new formulations of psychedelic drugs.
- Develops innovative delivery methods for psychedelics.
- Conducts clinical trials to evaluate the safety and efficacy of its products.
- Seeks regulatory approval for its psychedelic-based therapies.
- Commercializes approved psychedelic therapies for mental illness, neurological, and pain disorders.
How Does PHRRF Make Money?
- Develops and patents novel formulations and delivery methods for psychedelic drugs.
- Conducts clinical trials to demonstrate the efficacy and safety of its products.
- Seeks regulatory approval from agencies like the FDA.
- Partners with other companies for manufacturing, distribution, and commercialization.
What Industry Does PHRRF Operate In?
PharmaTher Holdings Ltd. operates within the rapidly evolving psychedelic medicine market. This market is driven by increasing awareness of the potential therapeutic benefits of psychedelics for mental health and neurological disorders. The competitive landscape includes both established pharmaceutical companies and emerging biotech startups. PharmaTher's focus on ketamine and innovative delivery methods differentiates it from competitors. The market is subject to evolving regulations and requires significant investment in research and development.
Who Are PHRRF's Key Customers?
- Patients suffering from mental illness, neurological disorders, and pain disorders.
- Healthcare providers who prescribe and administer psychedelic therapies.
- Hospitals and clinics that offer psychedelic-assisted treatments.
- Pharmaceutical companies that may license or acquire PharmaTher's products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Company Profile
PharmaTher Holdings Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Fabio Chianelli. PHRRF has traded publicly since 2021.
Financial Health
PharmaTher Holdings Ltd.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.98 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -15.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.64 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.1%, the inverse of the P/E and a quick read on earnings relative to price.
PHRRF Valuation & Market Position
With a $3.55M market cap, PharmaTher Holdings Ltd. sits in the micro-cap segment of the market.
Earnings Track Record
PharmaTher Holdings Ltd. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 28.0% above estimates on average.
Forward Outlook
Wall Street analysts project PharmaTher Holdings Ltd. revenue of about $27.6M for fiscal 2026, with EPS near $-0.08.
PHRRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Innovative drug delivery technologies (e.g., microneedle patch).
- Focus on ketamine, a well-studied psychedelic with established uses.
- Strategic collaborations with established companies.
- Pipeline of products in various stages of clinical trials.
Bear Case
- Limited financial resources as a clinical-stage company.
- Dependence on successful clinical trial outcomes.
- High regulatory hurdles for psychedelic-based therapies.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PHRRF Latest News
-
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Yahoo! Finance: PHRRF News · Aug 18, 2026
-
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
newsfilecorp.com · Aug 11, 2026
PHRRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PHRRF.
Price Targets
Wall Street price target analysis for PHRRF.
PHRRF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PHRRF; grades run from A+ (80-100) to F (below 30).
Latest News
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Leadership: Fabio Chianelli
CEO
Fabio Chianelli is the CEO of PharmaTher Holdings Ltd. His background includes experience in the pharmaceutical and biotechnology industries. He has held various leadership positions, focusing on corporate strategy, business development, and commercialization. His expertise spans across drug development, regulatory affairs, and market access. He has a proven track record of driving growth and innovation in the healthcare sector.
Track Record: Under Fabio Chianelli's leadership, PharmaTher Holdings Ltd. has advanced its pipeline of psychedelic-based therapies, including ketamine intravenous injection, ketamine patch, and ketamine pump. He has successfully secured collaboration agreements with key partners to accelerate product development and expand market reach. He has also overseen the company's efforts to develop innovative drug delivery technologies, such as the PHARMAPATCH microneedle patch.
PHRRF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PharmaTher Holdings Ltd. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, lower trading volume, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure requirements increase information asymmetry.
- Lower trading volume and liquidity can lead to price volatility.
- Higher potential for fraud or manipulation due to less regulatory oversight.
- OTC Other status may indicate financial distress or operational challenges.
- Increased risk of delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and cash flow.
- Review the company's OTC Markets profile and disclosure statements.
- Check for any regulatory actions or legal proceedings against the company.
- Consult with a financial advisor before investing.
- Collaboration agreements with reputable companies.
- Pipeline of products in clinical trials.
- Focus on addressing unmet medical needs.
- Experienced management team with relevant industry expertise.
- Development of innovative drug delivery technologies.
PHRRF Healthcare Stock FAQ
Is PHRRF a good stock to buy?
Stock Expert AI does not rate PHRRF buy, sell or hold. PharmaTher Holdings Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PHRRF stock price today?
The last price recorded on this page for PharmaTher Holdings Ltd. (PHRRF) is $0.039, as of the Oct 2, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for PHRRF?
The main risks for PharmaTher Holdings Ltd. include the uncertainty of clinical trial outcomes, the high regulatory hurdles for psychedelic-based therapies, and competition from established pharmaceutical companies.
What are the key factors to evaluate for PHRRF?
Evaluate PHRRF on fundamentals, analyst consensus, and risk factors. As of 2026-03-16, the company's market capitalization is $3.55M and P/E ratio is -4.66. Not financial advice.
How frequently does PHRRF data refresh on this page?
PHRRF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PHRRF's recent stock price performance?
PharmaTher Holdings Ltd. (PHRRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug delivery technologies (e. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHRRF overvalued or undervalued right now?
PharmaTher Holdings Ltd. (PHRRF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PHRRF before investing?
Before investing in PharmaTher Holdings Ltd. (PHRRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited and less reliable than data from major exchanges.
- Clinical trial outcomes are inherently uncertain and subject to change.